Your Article Summary
See Latest ArticlesRole of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Drug Resistance Updates, 06/17/09
Rapisarda A et al. - The current review focuses on the role of intra-tumor hypoxia as a mechanism of resistance to anti-angiogenic agents and speculates on therapeutic approaches that might circumvent resistance and thereby improve clinical outcome.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09
Taurolidine in the prevention and therapy of lung metastases
European Journal of Cardio-Thoracic Surgery, 12/18/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Selection and counterselection of the adefovir resistance mutation rtI233V during antiviral therapy
Journal of Clinical Microbiology, 12/18/09
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/18/09
Epidemiology and Evolution of Invasive Pneumococcal Disease Caused by Multidrug Resistant Serotypes of 19A in the 8 Years After Implementation of Pneumococcal Conjugate Vaccine Immunization in Dallas, Texas
The Pediatric Infectious Disease Journal, 12/17/09